T-cell mediated immune responses specific for peptides from the murine scFv antigen-binding domain of the CAR can develop in patients and result in premature elimination of CAR T-cells increasing ...

A recent study provides insight into how antigen binding primes T cells to be at the forefront of the immune response. The research team hypothesized that binding of the antigen to the T-cell receptor ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

9,10 (7) A T cell antigen coupler (TAC) and a TCR fusion construct (TRuC ... of CD3 signaling but also have high antigen sensitivity via the fusion of an antibody binding domain. This hybrid receptor ...

"So you have the start result—really tight binding—and ... High-affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells, Molecular Therapy ...

Chimeric antigen receptor (CAR)-T cells are ... "The fact that CAR molecules do not have a binding partner on other T cells further disproves the old hypothesis on how trogocytosis is regulated.

Here the authors characterise the function of a heparan sulphate binding region in amphiregulin ... to anti-PD-1 therapy in humans. T cell antigen receptor stimulation by the ligand antigen ...

NK cells are unlike T cells in that ... CD64 has greater binding activity for holding onto antigen-specific antibodies (which is critical for effective targeting) than any other molecule that ...

View Full Profile. Learn about our Editorial Policies. Chimeric antigen receptor (CAR) T cell therapy leverages patients’ immune systems to fight cancer. This immunotherapy greatly expanded treatment ...

The antibody's binding sites, located at the ends of its arms ... MHC class I molecules present peptides from intracellular antigens to CD8+ T cells, which are involved in the elimination of ...

EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, ...